SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PAGANELLI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.041
AS - Asia 5.562
EU - Europa 3.576
SA - Sud America 1.204
AF - Africa 110
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 6
Totale 22.510
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.851
SG - Singapore 2.543
PL - Polonia 1.290
CN - Cina 1.232
BR - Brasile 1.032
HK - Hong Kong 610
IT - Italia 481
DE - Germania 362
VN - Vietnam 351
TR - Turchia 343
UA - Ucraina 322
GB - Regno Unito 299
SE - Svezia 275
RU - Federazione Russa 196
ID - Indonesia 124
AR - Argentina 85
MX - Messico 84
CA - Canada 82
NL - Olanda 73
IN - India 61
ZA - Sudafrica 53
IE - Irlanda 52
BD - Bangladesh 46
AT - Austria 40
JP - Giappone 36
IQ - Iraq 34
FR - Francia 33
KR - Corea 29
JO - Giordania 26
EC - Ecuador 24
BE - Belgio 22
ES - Italia 22
FI - Finlandia 22
VE - Venezuela 18
CO - Colombia 14
PK - Pakistan 14
RO - Romania 14
AE - Emirati Arabi Uniti 13
MA - Marocco 12
SA - Arabia Saudita 12
AU - Australia 11
TN - Tunisia 11
DZ - Algeria 10
LT - Lituania 10
AZ - Azerbaigian 9
IR - Iran 9
CL - Cile 8
PT - Portogallo 8
UZ - Uzbekistan 8
KE - Kenya 7
PE - Perù 7
PY - Paraguay 7
BG - Bulgaria 6
BO - Bolivia 6
CH - Svizzera 6
CZ - Repubblica Ceca 6
GR - Grecia 6
NP - Nepal 6
JM - Giamaica 5
LB - Libano 5
MY - Malesia 5
PH - Filippine 5
RS - Serbia 5
SC - Seychelles 5
AL - Albania 4
DK - Danimarca 4
IL - Israele 4
KG - Kirghizistan 4
KH - Cambogia 4
KZ - Kazakistan 4
TT - Trinidad e Tobago 4
AO - Angola 3
BH - Bahrain 3
EG - Egitto 3
GE - Georgia 3
HR - Croazia 3
LV - Lettonia 3
MD - Moldavia 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
TW - Taiwan 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
CY - Cipro 2
ET - Etiopia 2
EU - Europa 2
GA - Gabon 2
GI - Gibilterra 2
HN - Honduras 2
KW - Kuwait 2
NI - Nicaragua 2
PA - Panama 2
PS - Palestinian Territory 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
Totale 22.497
Salva come PNG Salva come JPEG
Città #
Fairfield 1.499
Warsaw 1.285
Singapore 1.210
Ashburn 1.202
Woodbridge 1.181
Houston 761
Seattle 611
Hong Kong 605
Santa Clara 565
Chandler 551
Wilmington 496
Jacksonville 495
Cambridge 486
Ann Arbor 380
Beijing 347
Izmir 300
Dallas 250
Princeton 183
Nanjing 170
Los Angeles 162
Milan 130
Jakarta 106
San Diego 106
The Dalles 104
São Paulo 103
Boardman 101
Ho Chi Minh City 99
Columbus 97
Dearborn 94
Dong Ket 82
New York 72
Menlo Park 69
London 68
Nanchang 68
Moscow 66
Hanoi 63
Mexico City 56
Council Bluffs 52
Ferrara 52
Chicago 49
Hebei 45
Tianjin 45
Falls Church 42
Bologna 38
Shenyang 38
Buffalo 36
Tokyo 35
Mountain View 34
Rio de Janeiro 33
Shanghai 33
Brooklyn 32
Munich 31
Toronto 29
Nuremberg 28
Atlanta 27
Boston 27
Phoenix 27
Denver 26
Changsha 25
Jiaxing 25
San Francisco 25
Kunming 24
Redwood City 24
Rome 24
Stockholm 24
Washington 24
Belo Horizonte 23
Brussels 22
Johannesburg 22
Norwalk 22
Vienna 22
Montreal 21
Orange 19
Brasília 18
Poplar 18
Curitiba 17
Scottsdale 16
Amsterdam 15
Baghdad 15
Jinan 15
Porto Alegre 15
Fuzhou 14
Hangzhou 14
Addison 13
Biên Hòa 13
Frankfurt am Main 13
Haiphong 13
Orem 13
Seongnam 13
Helsinki 12
Seoul 12
Bremen 11
Guangzhou 11
Guarulhos 11
Pelotas 11
Santo André 11
Secaucus 11
Zhengzhou 11
Campinas 10
Charlotte 10
Totale 15.684
Salva come PNG Salva come JPEG
Nome #
Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors 494
Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival 344
A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions 269
Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images 255
Development of sentinel node localization and ROLL in breast cancer in Europe 246
A novel radioguided surgery technique exploiting β- decays 244
Positron emission tomography in the diagnostic work-up of screening-detected lung nodules 244
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 241
Improper use of "radioguided occult lesion localization" (ROLL) technique leads to misleading conclusions 226
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 226
Early use of abiraterone and radium-223 in metastatic prostate cancer 226
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice 217
Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging 213
Intramedullary spinal cord metastases from breast cancer: Detection with 18F-FDG PET/CT 197
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET 195
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study 194
Local accelerated radionuclide breast irradiation: Avidin-biotin targeting system 192
A parathyroid carcinoma within a cold thyroid nodule 187
Atypical primary pulmonary meningioma: A report of a case suspected of being a lung metastasis 185
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 185
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 184
Radioimmunotherapy in brain tumors 182
AvidinOX (TM) for highly efficient tissue-pretargeted radionuclide therapy 178
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study 177
68Ga- DOTA0-Tyr3octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours 172
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors 169
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 168
[18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning 165
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors 164
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas 163
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 163
Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status 162
3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART®) combined with external beam radiation therapy 159
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: Efficacy profile, safety, and quality of life 157
Intraoperative beta- detecting probe for radio-guided surgery of brain tumors 150
Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers 149
A delphic consensus assessment: Imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management 147
Nuclear medicine in the clinical management (ROLL, SNB, and PET) 147
Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: Preliminary results of EUDRACT/RSO 2016-002732-32 IRST protocol 147
177Lu specific activity influence over DOTATATE radiolabeling: experimental data 146
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest 146
[18 f]f-psma-1007 radiolabelling without an on-site cyclotron: A quality issue 146
Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening 145
Preoperative PET/CT in earlystage breast cancer: Is the TNM classification enough? 145
Sentinel lymph node biopsy in pregnant patients with breast cancer 144
Yttrium-labelled peptides for therapy of NET 144
Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: Results of a phase II study with 90Y-labeled biotin 143
Neuroendocrine tumors 142
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy 142
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 142
Long-term results of PRRT in advanced bronchopulmonary carcinoid 141
Yttrium-based therapy for neuroendocrine tumors 140
Development of sentinel node biopsy, ROLL and IART in early breast cancer at the European Institute of Oncology, Milan (IEO) 140
Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma 139
Dosimetry for treatment with radiolabelled somatostatin analogues. A review 139
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 138
Positron emission tomography for the detection of colorectal adenomas 137
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC 136
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors 136
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging 135
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies 135
Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests 135
Financial aspects of sentinel lymph node biopsy in early breast cancer 135
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 135
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma 134
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors 134
Investigation of 90Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I-II clinical study 134
Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases 134
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours 133
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 133
PET/CT and breast cancer subtypes 132
Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 132
Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin) 131
Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules 130
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution 130
OXavidin for tissue targeting biotinylated therapeutics 129
Treatment of a pituitary metastasis from a neuroendocrine tumour: Case report and literature review 128
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients 127
Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin 127
SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes 127
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study 127
Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma 127
Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: Preliminary results 127
Calculation of electron and isotopes dose point kernels with fluka Monte Carlo code for dosimetry in nuclear medicine therapy 126
Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? 125
Radioembolisation with 90Y-microspheres: Dosimetric and radiobiological investigation for multi-cycle treatment 125
Erratum: Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 124
The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function 124
Therapeutic use of avidin is not hampered by antiavidin antibodies in humans 124
Detection of a cardiac mass by [18F]FDG-PET/CT: A rare case 124
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy 122
An unusual breast lesion: The ultrasonographic, mammographic, MRI and nuclear medicine findings of mammary hibernoma 122
Hematologic toxicity and double autografting of stem cells after myeloablative activities of Yttrium-90-Ibritumomab tiuxetan 122
Hibernoma mimicking metastasis on positron emission tomography-computed tomography imaging: A misleading finding in oncologic patient follow-up 122
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series 122
PET imaging of HER-2-positive tumours 120
Preoperative FDG PET/CT in breast cancer patients: Where are we going? 118
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL) 117
Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas 116
Nonpalpable breast carcinomas: Long-term evaluation of 1,258 cases 116
Totale 15.934
Salva come PNG Salva come JPEG
Categoria #
all - tutte 128.371
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.366
Totale 132.737
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.702 0 0 0 0 0 422 132 309 86 315 180 258
2021/20221.303 84 64 35 47 21 133 82 142 69 160 107 359
2022/20231.635 184 44 75 181 195 246 122 151 190 12 148 87
2023/2024881 89 86 64 33 77 131 41 37 22 23 28 250
2024/20254.132 58 97 333 157 510 407 151 253 697 608 646 215
2025/20265.178 862 523 1.044 1.089 1.532 128 0 0 0 0 0 0
Totale 23.054